The Food and Drug Administration has emptied a new artificial intelligence-driven X-ray device that manufacturer GE Healthcare says reduces the time to diagnose and treat a collapsed lung from eight hours to as little as 15 minutes, the company announced Thursday.
The device, called the Critical Care Suite, uses AI algorithms to scan x-rays and detect pneumothorax, a fatal condition more commonly known as a collapsed lung that affects about 74,000 Americans each year.
"The health care industry produces huge amounts of data from images to digital health records," GE Healthcare CEO Kieran Murphy said in an interview with CNBC ahead of the announcement. "We strongly believe that you need to turn this data into information and insight to improve results."
GE Healthcare, a dominant player in hospital and laboratory equipment, stated that the goal is to integrate AI into all aspects of health care. system to ultimately "improve patient outcomes, reduce waste and inefficiency, and eliminate costly errors."
The General Electric device's technology, developed by a researcher at the University of California, San Francisco, is trained to detect pneumothorax, but the company said it is working to improve it to detect other health conditions.
The technology works by using AI to analyze X-ray images, the company says. If a condition is suspected ̵
"Currently, 62% of portable breast exams are labeled & # 39; STAT & # 39; or for urgent reading, but they are not all critical," said Jie Xue, president and CEO of the company's X-ray department. "This creates a delay in the turnaround for really critical patients, which can be a serious problem."
FDA approval comes at a time when AI is expanding across the medical field, helping physicians quickly analyze a variety of illnesses and diseases, reducing costs and inefficiencies. While there is optimism, there are also concerns that technology is making major medical decisions.
"There are no indications that you are replacing the radiologist," Murphy said in the interview. "Of course, [the radiologist] will check that they agree with the conclusion. But for the moment, the accuracy of large pneumonia of 96% and a very low number of false ones is also a problem of course."
The unit is expected to hit the US market this year.
The health care system has grown dramatically from its origins in 1896 as it began to develop x-rays. The company has become a leader in medical health care. It is already a dominant player in hospital and laboratory equipment and is a growing force in medical records, software for health care and has expanded its focus on gene therapy research.
In February, GE announced plans to sell its biopharma stake to industrial company Danaher for $ 21.4 billion.